The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTotally Regulatory News (TLY)

Share Price Information for Totally (TLY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.70
Bid: 4.50
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.50 (11.111%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4.70
TLY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

29 Sep 2017 11:45

RNS Number : 2638S
Totally PLC
29 September 2017
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

 

29 September 2017

 

Totally PLC

("Totally", "the Company" or "the Group")

 

Half-year results for the six months ended 30 June 2017

 

Totally (AIM: TLY), the provider of a range of services to the healthcare sector, announces its interim results for the six months ended 30 June 2017 ("H1 2017").

 

Highlights

· Significant progress made towards delivering a progressive 'buy and build' strategy, aimed at establishing Totally as a leading provider of 'out of hospital' care in the UK.

· Three acquisitions completed in 2016 and fully integrated in H1 2017: Premier Physical Healthcare Ltd ("Premier"), About Health Ltd ("About Health") and Optimum Sports Performance Centre ("Optimum") - all provide a range of preventative and responsive healthcare services in community settings, GP surgeries and patients' homes, from pre-diagnosis through to discharge.

· The subsidiaries are continuing to secure new businesses and renew existing contracts including:

o About Health awarded a new £130,000 12 month contract with Harrogate and Rural District CCG - January 2017

o Premier awarded a new contract worth £140,000p.a. over three years with NHS Care & Custody - March 2017

o Premier awarded two five year contracts for approximately £340,000 with Care UK - April 2017

o Premier secured six year £400,000 contract with Care UK and South Yorkshire Prisons - September 2017

o About Health awarded £331,750 p.a. four year contract to provide dermatology services to Castle Point, Rochford and Southend CCGs, UK - September 2017

· At an advanced stage of due diligence and finalising terms to complete an acquisition as announced 21 July 2017, which will constitute a reverse takeover under the AIM Rules - Totally to update market first half October 2017

· Continuing to evaluate further value accretive acquisition opportunities focused on the UK NHS outsourced healthcare services market, estimated to be worth in the region of £20 billion per year 

 

Financial Overview

· Group turnover: £3,676,000 (H1 2016: £936,000)

· Gross profit: £1,169,000 (H1 2016: £286,000)

· EBITDA loss excluding exceptional costs: £657,924 (H1 2016: EBITDA loss £403,000)

· EBITDA loss including exceptional costs: £740,385 (H1 2016: EBITDA loss £841,000)

 

 

 

 

 

Chairman Statement

I am pleased to report on the half year period, a time which has not only seen us successfully integrate our three acquisitions completed in 2016, which are all generating revenues and performing well, but also aggressively progress our buy and build strategy as we continue to act as a consolidator in the fragmented UK healthcare market and build ourselves as the leading out of hospital healthcare services provider.

 

Our oversubscribed £17.6m placing and open offer completed in March this year was intended to fund potential acquisitions in line with our buy and build strategy. To this end, Totally announced on 21 July 2017 that they had signed heads of terms on a potential acquisition that would constitute a reverse takeover under the AIM Rules. The shares were suspended at this time and remain suspended at the current time. Whilst the acquisition and due diligence process has taken longer than envisaged to complete we are now at a very advanced stage and are confident that the acquisition, which constitutes a reverse takeover, will be completed imminently and we look forward to updating the market in this regard in the first half of October 2017.

 

We are confident that, when completed, the acquisition will add significant scale to the Group and diversify the services provided by the Group, as well as see us continue to deliver on our stated vision of building Totally as the pre-eminent provider of out of hospital services to help address some of the challenges the UK faces in terms of healthcare and in turn deliver shareholder value through the growth of the Group.

 

Our existing businesses (Totally Health and My Clinical Coach), which were part of the Company prior to the formation of the new Board in November 2015 and subsequent buy and build growth strategy, performed below management expectations in the first half, but through the services they offer have been supportive of the growth in the acquired businesses ensuring streamlined costs and economies of scales to benefit the plc bottom line.

 

To this end, in addition to finalising our near-term acquisition, we continue to seek out and have a number of further opportunities in the pipeline as we continue to build a profitable platform for growth for the Group.

 

The six months' results showed turnover of £3,675,521 (2016: £936,000) and a loss of £961,000 (2016: £844,000).

 

Whilst the first half of 2017 has seen slower than anticipated growth, we remain cautiously optimistic on the outcome for the financial year ending 31 December 2017 based on recent trading performance and the short term pipeline of new opportunities.

 

On behalf of the Board, it would be remiss of me not to thank all stakeholders for their patience and we look forward to updating the market in the near-term on the outlined developments in due course.

 

Bob Holt

Chairman

29 September 2017

 

 

Operational Review

I can only echo the comments made above by our Chairman, Bob Holt. The first half of 2016 was a transformational period for Totally, and this progress continues across the Group into 2017. The first two acquisitions are already proving to be very successful and are adding to the Group's range of out of hospital services, along with the expertise of the people within those companies. The integration of the new businesses into the Group has already opened up new business opportunities, and as we continue to grow I am confident that we will deliver our stated aim to become one of the UK's leading providers of 'out of hospital' services.

 

Both Premier Physical Healthcare and About Health have seen successes since joining the Group, with new contract wins and the securing of contract renewals supported by Optimum. The existing businesses, Totally Health incorporating My Clinical Coach, have struggled to build new business streams in the period but continue to support all Group business.

 

As well as thanking all of our shareholders for their continued support, I would also like to thank everyone who is part of 'Team Totally' as it is their commitment and approach that enables us to deliver the high quality services to patients and customers across the Group.

 

 

Wendy Lawrence

Chief Executive Officer

29 September 2017

 

Financial Review

 

During the first half of 2017, the Group continued to invest in IT and staff to build a suitable infrastructure to best position the Group to execute its buy and build strategy. This investment will help to identify and streamline business processes, in terms of the bid process, clinical governance, administration and collaboration across the Group's companies. It is envisaged that this will result in cost savings through economies of scale and a move to a shared service model where appropriate.

 

In addition to cost savings, the Group companies will also be able to collaborate on larger and more integrated bids. The collaboration and infrastructure investment should allow for increasingly competitive bid offerings. These bids will be underpinned by efficient delivery of services, while maintaining quality and profit margin.

 

The Loss Before Tax to 30 June 2017 includes an amortisation charge of £220,000 relating to intangible assets (2016: £nil).

 

Donald Baladasan

Chief Financial Officer

29 September 2017

 

 

 

 

 

For further information please contact:

Totally plc

020 3866 3335

Wendy Lawrence, Chief Executive

Bob Holt, Chairman

Allenby Capital Limited (Nominated Adviser & Joint Broker)

020 3328 5656

Nick Athanas

Virginia Bull

James Thomas

Cenkos Securities Plc (Joint Broker)

020 7397 8900

Bobbie Hilliam

 

Yellow Jersey PR

+44 (0)203 735 8825

 

Felicity Winkles

Georgia Colkin

Joe Burgess

 

 

Interim Consolidated Income Statement

For the six months ended 30 June 2017

 

Six months ended 30 June 2017

Six months ended 30 June 2016*

Year ended 31 December 2016

(Unaudited)

(Unaudited)

(Audited)

£000

£000

£000

Revenue

3,676

936

3,977

Cost of sales

(2,507)

(650)

(2,600)

Gross profit

1,169

286

1,377

Administrative expenses

(1,826)

(689)

(2,536)

Exceptional items

(83)

(438)

(494)

Loss before interest, tax and depreciation

(740)

(841)

(1,653)

Depreciation

(11)

(3)

(24)

Amortisation

(220)

-

(645)

Operating loss

(971)

(844)

(2,322)

Finance income

-

-

830

Finance costs

(11)

-

-

Loss before taxation

(982)

(844)

(1,492)

Income tax

21

-

(24)

Loss from continuing operations

(961)

(844)

(1,516)

Loss attributable to the equity shareholders of the parent company

(961)

(844)

(1,516)

 

Earnings per share (Note 2)

Basic and diluted: Pence

Continuing operations

(5)

(5)

(8)

Loss per share

(5)

(5)

(8)

 

* The Group's 2016 half yearly financial results include the financial performance of Totally plc and Totally Health for the full half year, the three months from April to June 2016 for Premier Physical Healthcare Limited and half of June 2016 for About Health Limited.

 

The accompanying notes form part of the unaudited interim report.

 

 

 

 

 

Interim Consolidated Statement of Changes in Equity

For the six months ended 30 June 2017

 

Share capital

Share premium

Profit and loss

Equity shareholders'

account

account

funds

£000

£000

£000

£000

At 1 January 2016 (Audited)

3,055

4,534

(7,097)

492

Comprehensive loss for the year (Unaudited)

-

-

(844)

(844)

Issue of share capital (Unaudited)

Credit on issue of warrants and options (Unaudited)

1,000

-

5,110

-

-

14

6,110

14

At 30 June 2016 (Unaudited)

4,055

9,644

(7,927)

5,772

 

 

At 1 January 2016 (Audited)

3,055

4,534

(7,097)

492

Comprehensive loss for the year (Audited)

-

-

(1,516)

(1,516)

Issue of share capital (Audited)

1,002

5,120

-

6,122

Credit on issue of warrants and options (Audited)

-

-

25

25

Deferred shares buy-back(Audited)

(2,055)

-

2,055

-

Share premium cancellation (Audited)

-

(9,645)

9,645

-

At 31 December 2016 (Audited)

2,002

9

3,112

5,123

 

 

At 1 January 2017 (Audited)

2,002

9

3,112

5,123

Comprehensive loss for the year (Unaudited)

-

-

(961)

(961)

Issue of share capital (Unaudited)

3,200

13,447

-

16,647

Credit on issue of options (Unaudited)

-

-

16

16

At 30 June 2017 (Unaudited)

5,202

13,456

2,167

20,825

 

The accompanying notes form part of the unaudited interim report

Interim Consolidated Statement of Financial Position

As at 30 June 2017

 

30 June 2017

30 June 2016

31 December 2016

(Unaudited)

(Unaudited)

(Audited)

£000

£000

£000

Non-Current Assets

Intangible fixed assets

12,482

12,898

12,669

Fixed assets

101

25

95

12,583

12,923

12,764

Current Assets

Inventory

6

-

6

Trade and other receivables

1,934

1,115

2,047

Cash and cash equivalent

16,787

2,947

998

18,727

4,062

3,051

Total Assets

31,310

16,985

15,815

Current Liabilities

Trade and other payables

(771)

(827)

(879)

Corporation tax

(27)

-

(43)

Borrowings / Invoice discounting

(76)

(80)

(62)

Deferred acquisition consideration

(1,641)

(2,804)

(1,641)

(2,515)

(3,711)

(2,625)

Long Term Liabilities

Deferred acquisition consideration

(7,941)

(7,477)

(8,018)

Borrowings

(15)

-

(15)

Deferred tax

(14)

-

(9)

(7,970)

(7,502)

(8,067)

Total Liabilities

10,485

11,213

(10,692)

Net Current Assets

16,212

351

426

Net Assets

20,825

5,772

5,123

Shareholders' Equity

Share capital

5,202

4,055

2,002

Share premium account

 13,456

9,644

9

Retained earnings

2,167

(7,927)

3,112

Equity shareholders' funds/ (deficit)

20,825

5,772

5,123

 

 

 

The accompanying notes form part of the unaudited interim report

 

 

 

 

 

 

Interim Consolidated Cash Flow Statement

For the six months ended 30 June 2017

 

Six months ended 30 June 2017

Six months ended 30 June 2016

Year ended 31 December 2016

(Unaudited)

(Unaudited)

(Audited)

£000

£000

£000

Cash flow from operating activities:

Loss for the period

(961)

(844)

(1,516)

Adjustments for:

Amortization and depreciation

Options and warrants charge

231

16

3

14

669

25

Tax expense/(income) recognised in profit and loss

(21)

-

24

Finance income

-

-

(830)

Finance costs

11

-

-

Movements in working capital:

Movement in trade and other receivables

113

(179)

(503)

Movement in trade and other payables

(91)

158

(25)

Cash generated from operations

(702)

(848)

(2,156)

 Income tax received/ (paid)

9

-

(51)

Net cash flows from operating activities

(693)

(848)

(2,207)

Cash flow from investing activities:

Purchases of property, plant and equipment

(17)

(10)

(34)

Development of intangible assets

(58)

(322)

(495)

Deferred consideration payment

(86)

-

-

Accrued preference shares interest paid

(18)

(2,342)

(2,756)

Net cash flows from investing activities

(179)

(2,674)

(3,285)

Cash outflow before financing

(872)

(3,522)

(5,492)

Cash flow from financing activities:

Issue of share capital, net

16,647

-

(6,122)

Borrowings/invoice discounting increase

16

-

19

Finance lease payments

(2)

-

(10)

Net cash flow from financing activities

16,661

6,110

6,131

Net increase in cash and cash equivalents

15,789

2,588

639

Cash and cash equivalents at beginning of the period

998

359

359

Cash and cash equivalents at end of the period

16,787

2,947

998

 

 

The accompanying notes form part of the unaudited interim report

 

 

 

 

 

 

 

 

 

 

Notes to the Interim Results

 

1. Basis of preparation

 

Totally plc is a public limited company incorporated in the United Kingdom under the Companies Act 2006 (registration number: 3870101). The Company's ordinary shares are admitted to trading on the AlM Market of the London Stock Exchange ("AIM").

 

The Group's principal activities in the period under review have been the provision of innovative solutions to the healthcare sector, which are provided by the Group's wholly owned subsidiaries, Totally Health Limited (incorporating MyClinicalCoach), Premier Physical Healthcare Limited, About Health Limited and Optimum Sports Performance Centre Limited.

 

The interim report and accounts for the six months ended 30 June 2017 have been prepared using the recognition and measurement principles of International Financial Reporting Standards and Interpretations as endorsed by the European Union (collectively "Adopted IFRS").

 

These condensed consolidated interim financial statements for the half-year ended 30 June 2017 have been prepared in accordance with the AIM Rules for Companies and should be read in conjunction with the annual financial statements for the year ended 31 December 2016, which have been prepared in accordance with IFRS as adopted by the European Union. The interim report and accounts do not include all the information and disclosures required in the annual financial statements.

 

The interim report and accounts have been prepared on the basis of the accounting policies set out in the Group's 2016 Annual Report and Accounts and on the basis of the principal accounting policies that the Group expects to apply in its financial statements for the year ending 31 December 2017.

 

The interim report and accounts do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. These condensed consolidated interim financial statements were approved by the Board of Directors on 29 September 2017. The results for the six months to 30 June 2017 and the comparative results for six months to 30 June 2016 are unaudited. The comparative figures for the year ended 31 December 2016 do not constitute the statutory financial statements for that year.

 

As at 30 June 2017 net current assets totalled £16.2m (30 June 2015: £0.4m) comprised of cash balances of £16.8m, trade and other receivables of £1.9m less current liabilities of £2.5m. The current liabilities include deferred contingent consideration of £1.6m for acquisitions made in 2016.

 

Cash generation by the Group over the next year is expected to contribute to covering future liabilities. The Directors believe that a combination of the Group's current cash, projected revenues from existing and future contracts and continued shareholder support will enable the Group to meet its obligations and to implement its business plan in full. Inherently, there can be no certainty in these matters, but the Directors believe that the Group's internal trading forecasts are realistic and that the going concern basis of preparation continues to be appropriate.

 

 

 

 

2. Earnings per share

Basic loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.

None of the share options or warrants in issue had a dilutive effect on earnings per share.

 

Six months ended 30 June 2017

Six months ended 30 June 2016

Year ended 31 December 2016

(Unaudited)

(Unaudited)

(Audited)

Loss (continuing operations) (£000)

(961)

(844)

(1,516)

Weighted average number of shares used

in basic and diluted earnings ('000)

19,109

15,860

17,973

Basic and diluted earnings per share (continuing operations) (Pence)

(5)

(5)

(8)

 

 

4. Dividends

 

No dividend is proposed for the six months ended 30 June 2017.

 

5. Events after the reporting period

 

(a) On 18 July 2017, the Company announced that the second deferred payment for Premier Physical Healthcare Limited of £1,156,712 being settled through the payment of £863,681 in cash, the issue of loan notes with an aggregate nominal value of £61,691 and the issue of 480,957 new ordinary shares of 10 pence each at a price of 48.1 pence per share pursuant to the terms of the acquisition.

 

(b) On 21 July 2017, the Company confirmed that the Company has signed heads of terms on a potential acquisition which would constitute a reverse takeover under rule 14 of the AIM Rules for Companies.

The potential acquisition would be consistent with the Company's strategy, as outlined at the time of its fundraising in February 2017, to create shareholder value through identifying attractive acquisition opportunities and acting as a consolidator in the current fragmented UK healthcare industry.

 

(c) On 1 September 2017, Premier Physical Healthcare Limited, a wholly owned subsidiary of Totally plc, won a £403,848 six-year contract with Care UK and South Yorkshire Prisons.

 

(d) On 6 September 2017, About Health Limited, a wholly owned subsidiary of Totally plc, secured a four-year contract to provide dermatology services to Castle Point, Rochford and Southend CCGs. The contract revenue is £331,750 per annum.

 

 

 

 

6. Distribution of Interim Report

A copy of the interim report will be available shortly on the Company's website (www.totallyplc.com) in accordance with Rule 26 of the AIM Rules for Companies and copies will also be available from the Company's registered office located at Hamilton House, Mabledon Place, London WC1H 9BB.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR BGGDCXSDBGRC
Date   Source Headline
19th Apr 20245:15 pmRNSHolding(s) in Company
19th Apr 20243:00 pmRNSHolding(s) in Company
11th Mar 20247:00 amRNSContract win
7th Mar 20246:00 pmRNSHolding(s) in Company
5th Feb 20247:00 amRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSDirectorate Change
10th Jan 20247:00 amRNSContract Extension
8th Dec 20233:30 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSDirector/PDMR Shareholding
4th Dec 20235:45 pmRNSHolding(s) in Company
1st Dec 20239:33 amRNSDirector/PDMR Shareholding
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSAdviser Update
28th Nov 20237:00 amRNSDirectorate Change
28th Nov 20237:00 amRNSInterim Results
22nd Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
4th Oct 20234:15 pmRNSHolding(s) in Company
11th Sep 202312:00 pmRNSExercise of options and change to TVR
1st Sep 202312:25 pmRNSResult of AGM
1st Sep 20237:00 amRNSAGM Statement
25th Jul 20237:00 amRNSHolding(s) in Company
18th Jul 20234:00 pmRNSExercise of options and change to TVR
13th Jul 20233:30 pmRNSHolding(s) in Company
12th Jul 202312:15 pmRNSHolding(s) in Company
12th Jul 20237:00 amRNSDividend Timetable and EPS - Corrections
11th Jul 20237:00 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSPreliminary results
6th Jul 20237:00 amRNSNotice of Preliminary Results
5th Jul 20231:00 pmRNSExercise of options and change to TVR
22nd May 20237:00 amRNSTotally secures multiple contract extensions
16th May 202312:30 pmRNSExercise of options & change to TVR
2nd May 20237:01 amRNSTrading Update for 12 months ending 31 March 2023
2nd May 20237:00 amRNSAppointment of Nomad and Joint Corporate Broker
26th Apr 20237:00 amRNSFurther new contract win for urology services
18th Apr 20237:00 amRNSTotally to help reduce waiting lists in Wales
12th Apr 20237:00 amRNSTotally wins new contract for urology services
4th Apr 20237:00 amRNSTotally first to fully mobilise on NHS SVCC model
31st Mar 20235:00 pmRNSTotal Voting Rights
31st Mar 20237:00 amRNSDirector/PDMR Shareholding
20th Mar 20231:42 pmRNSExercise of options, PDMR shareholding & TVR
16th Mar 20231:34 pmRNSDirector/PDMR Shareholding
10th Mar 20231:49 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 20232:09 pmRNSDirector/PDMR Shareholding
2nd Mar 20239:05 amRNSSecond Price Monitoring Extn
2nd Mar 20239:00 amRNSPrice Monitoring Extension
2nd Mar 20237:00 amRNSTrading Update
28th Feb 20235:00 pmRNSTotal Voting Rights
3rd Feb 20234:41 pmRNSExercise of options, director/PDMR & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.